News
Stay up to date on the latest crypto trends with our expert, in-depth coverage.
1SEC crypto safe harbor heads to White House review, proposal due 'shortly' says Atkins2Nvidia CoWoS production capacity to reach 650,000 units in 2026, up 76% year-on-year; 840,000 units in 2027. Next-generation Rubin GPU mass production target lowered from 2 million to 1.5 million units due to HBM4 validation delays.3Geopolitical Pause or Rising Tensions? Markets Brace for Iran's Critical Deadline
Skillsoft Surges on Thin Volume—Breakout or False Signal?
101 finance·2026/04/07 21:43
Smart investors seize Meta's downturn as uncertainties grow over AI investments and potential legal challenges
101 finance·2026/04/07 21:43
ASUR's Colombia Surge vs. Mexico Reversal Creates Event-Driven Trade Setup
101 finance·2026/04/07 21:42
Elon Musk Offloads $11 Billion in Tesla Shares Ahead of Trial—Savvy Investors Spot Danger, Not Profit
101 finance·2026/04/07 21:42
Akanda’s April 27 Quorum Trial: A Decisive Trigger for a Stock That Has Already Factored in Defeat
101 finance·2026/04/07 21:42
ZEC (Zcash) fluctuates 23% in 24 hours, trading volume surges 77%, whale buying becomes key driver
Bitget Pulse·2026/04/07 21:39
AI Stock Downturn: Top 5 Stocks Worth Investing in Today
101 finance·2026/04/07 21:37
Flash
21:42
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), Supernus Pharmaceuticals has reached an agreement to acquire the asset portfolio related to the candidate drug NV-5138 (also known as SPN-820).The subject of this transaction covers not only the core intellectual property rights of the drug, but also its existing inventory. This move marks an important step forward in Supernus Pharmaceutical's strategy to expand its product pipeline.
21:41
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), Supernus Pharmaceuticals officially signed an asset purchase agreement with Navitor on April 1, 2026.This move marks a significant milestone for both companies in asset trading.
21:41
According to a document submitted to the U.S. Securities and Exchange Commission (SEC), the purchase price structure for Supernus Pharmaceuticals not only includes the ongoing Phase 2B clinical research, but also potential future milestone payments, with the total amount reaching up to $350 million.This arrangement highlights the high recognition of the future potential of the relevant asset in this transaction. Milestone payments are usually linked to key milestones in the R&D process or future commercialization results. The potential maximum payment of up to $350 million in this case undoubtedly sends a positive signal to the market regarding the asset's prospects.
News